BACKGROUND: Evidence suggests reduced survival rates following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in people with preexisting mental disorders, especially psychotic disorders, before the broad introduction of vaccines. It remains unknown whether this elevated mortality risk persisted at later phases of the pandemic and when accounting for the confounding effect of vaccination uptake and clinically recorded physical comorbidities. METHODS AND FINDINGS: We used data from Czech national health registers to identify first-ever serologically confirmed SARS-CoV-2 infections in 5 epochs related to different phases of the pandemic: 1st March 2020 to 30th September 2020, 1st October 2020 to 26th December 2020, 27th December 2020 to 31st March 2021, 1st April 2021 to 31st October 2021, and 1st November 2021 to 29th February 2022. In these people, we ascertained cases of mental disorders using 2 approaches: (1) per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes for substance use, psychotic, affective, and anxiety disorders; and (2) per ICD-10 diagnostic codes for the above mental disorders coupled with a prescription for anxiolytics/hypnotics/sedatives, antidepressants, antipsychotics, or stimulants per the Anatomical Therapeutic Chemical (ATC) classification codes. We matched individuals with preexisting mental disorders with counterparts who had no recorded mental disorders on age, sex, month and year of infection, vaccination status, and the Charlson Comorbidity Index (CCI). We assessed deaths with Coronavirus Disease 2019 (COVID-19) and from all-causes in the time period of 28 and 60 days following the infection using stratified Cox proportional hazards models, adjusting for matching variables and additional confounders. The number of individuals in matched-cohorts ranged from 1,328 in epoch 1 to 854,079 in epoch 5. The proportion of females ranged from 34.98% in people diagnosed with substance use disorders in epoch 3 to 71.16% in individuals diagnosed and treated with anxiety disorders in epoch 5. The mean age ranged from 40.97 years (standard deviation [SD] = 15.69 years) in individuals diagnosed with substance use disorders in epoch 5 to 56.04 years (SD = 18.37 years) in people diagnosed with psychotic disorders in epoch 2. People diagnosed with or diagnosed and treated for psychotic disorders had a consistently elevated risk of dying with COVID-19 in epochs 2, 3, 4, and 5, with adjusted hazard ratios (aHRs) ranging from 1.46 [95% confidence intervals (CIs), 1.18, 1.79] to 1.93 [95% CIs, 1.12, 3.32]. This patient group demonstrated also a consistently elevated risk of all-cause mortality in epochs 2, 3, 4, and 5 (aHR from 1.43 [95% CIs, 1.23, 1.66] to 1.99 [95% CIs, 1.25, 3.16]). The models could not be reliably fit for psychotic disorders in epoch 1. People diagnosed with substance use disorders had an increased risk of all-cause mortality 28 days postinfection in epoch 3, 4, and 5 (aHR from 1.30 [95% CIs, 1.14, 1.47] to 1.59 [95% CIs, 1.19, 2.12]) and 60 days postinfection in epoch 2, 3, 4, and 5 (aHR from 1.22 [95% CIs, 1.08, 1.38] to 1.52 [95% CIs, 1.16, 1.98]). Cases ascertained based on diagnosis of substance use disorders and treatment had increased risk of all-cause mortality in epoch 2, 3, 4, and 5 (aHR from 1.22 [95% CIs, 1.03, 1.43] to 1.91 [95% CIs, 1.25, 2.91]). The models could not be reliably fit for substance use disorders in epoch 1. In contrast to these, people diagnosed with anxiety disorders had a decreased risk of death with COVID-19 in epoch 2, 3, and 5 (aHR from 0.78 [95% CIs, 0.69, 0.88] to 0.89 [95% CIs, 0.81, 0.98]) and all-cause mortality in epoch 2, 3, 4, and 5 (aHR from 0.83 [95% CIs, 0.77, 0.90] to 0.88 [95% CIs, 0.83, 0.93]). People diagnosed and treated for affective disorders had a decreased risk of both death with COVID-19 and from all-causes in epoch 3 (aHR from 0.87 [95% CIs, 0.79, 0.96] to 0.90 [95% CIs, 0.83, 0.99]), but demonstrated broadly null effects in other epochs. Given the unavailability of data on a number of potentially influential confounders, particularly body mass index, tobacco smoking status, and socioeconomic status, part of the detected associations might be due to residual confounding. CONCLUSIONS: People with preexisting psychotic, and, less robustly, substance use disorders demonstrated a persistently elevated risk of death following SARS-CoV-2 infection throughout the pandemic. While it cannot be ruled out that part of the detected associations is due to residual confounding, this excess mortality cannot be fully explained by lower vaccination uptake and more clinically recorded physical comorbidities in these patient groups.

3rd Faculty of Medicine Charles University Prague Czech Republic

Clinical Center National Institute of Mental Health Klecany Czech Republic

Department of Clinical Epidemiology Aarhus University Aarhus Denmark

Department of Epidemiology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Neurology Columbia University Irving Medical Center Columbia University New York New York United States

Department of Psychiatry Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Psychiatry University of Cambridge Cambridge United Kingdom

Department of Public Mental Health National Institute of Mental Health Klecany Czechia

Health Service and Population Research Department Institute of Psychiatry Psychology and Neuroscience King's College London London United Kingdom

Institute of Health Information and Statistics of the Czech Republic Prague Czech Republic

PROMENTA Research Center Department of Psychology University of Oslo Oslo Norway

Zobrazit více v PubMed

Momen NC, Plana-Ripoll O, Agerbo E, Benros ME, Børglum AD, Christensen MK, et al.. Association between Mental Disorders and Subsequent Medical Conditions. N Engl J Med. 2020;382(18):1721–1731. doi: 10.1056/NEJMoa1915784 PubMed DOI PMC

Schneider F, Erhart M, Hewer W, Loeffler LAK, Jacobi F. Mortality and medical comorbidity in the severely mentally ill—a German registry study. Dtsch Arztebl Int. 2019;116(23–24):405–411. doi: 10.3238/arztebl.2019.0405 PubMed DOI PMC

Scott KM, Lim C, Al-Hamzawi A, Alonso J, Bruffaerts R, Caldas-de-Almeida JM, et al.. Association of Mental Disorders With Subsequent Chronic Physical Conditions: World Mental Health Surveys From 17 Countries. JAMA Psychiatry. 2016;73(2):150–158. doi: 10.1001/jamapsychiatry.2015.2688 PubMed DOI PMC

Plana-Ripoll O, Pedersen CB, Agerbo E, Holtz Y, Erlangsen A, Canudas-Romo V, et al.. A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. Lancet. 2019;394(10211):1827–1835. doi: 10.1016/S0140-6736(19)32316-5 PubMed DOI

Plana-Ripoll O, Weye N, Momen NC, Christensen MK, Iburg KM, Laursen TM, et al.. Changes Over Time in the Differential Mortality Gap in Individuals With Mental Disorders. JAMA Psychiatry. 2020. doi: 10.1001/jamapsychiatry.2020.0334 PubMed DOI PMC

Melo APS, Dippenaar IN, Johnson SC, Weaver ND, de Assis AF, Malta DC, et al.. All-cause and cause-specific mortality among people with severe mental illness in Brazil’s public health system, 2000–15: a retrospective study. Lancet Psychiatry. 2022;9(10):771–781. doi: 10.1016/S2215-0366(22)00237-1 PubMed DOI PMC

Lumme S, Pirkola S, Manderbacka K, Keskimäki I. Excess Mortality in Patients with Severe Mental Disorders in 1996–2010 in Finland. PLoS ONE. 2016;11(3). doi: 10.1371/journal.pone.0152223 PubMed DOI PMC

Wang Q, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021;20(1):124–130. doi: 10.1002/wps.20806 PubMed DOI PMC

Nishimi K, Neylan TC, Bertenthal D, Seal KH, O’Donovan A. Association of Psychiatric Disorders With Incidence of SARS-CoV-2 Breakthrough Infection Among Vaccinated Adults. JAMA Netw Open. 2022;5(4):e227287–e. doi: 10.1001/jamanetworkopen.2022.7287 PubMed DOI PMC

Blom JD, Martínez-González MÁ, Molendijk ML, Molero P, Reina G, Reinken A, et al.. COVID-19 risk, course and outcome in people with mental disorders: a systematic review and meta-analyses. Epidemiol Psychiatr Sci. 2023:32. doi: 10.1017/S2045796023000719 PubMed DOI PMC

Teixeira AL, Krause TM, Ghosh L, Shahani L, Machado-Vieira R, Lane SD, et al.. Analysis of COVID-19 Infection and Mortality Among Patients With Psychiatric Disorders, 2020. JAMA Netw Open. 2021;4(11). doi: 10.1001/jamanetworkopen.2021.34969 PubMed DOI PMC

Jeon H-L, Kwon JS, Park S-H, Shin J-Y. Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: nationwide cohort study. Br J Psychiatry. 2021;218(6):344–351. doi: 10.1192/bjp.2020.251 PubMed DOI

Yang H, Chen W, Hu Y, Chen Y, Zeng Y, Sun Y, et al.. Pre-pandemic psychiatric disorders and risk of COVID-19: a UK Biobank cohort analysis. Lancet Healthy Longev. 2020;1(2):e69–e79. doi: 10.1016/S2666-7568(20)30013-1 PubMed DOI PMC

Goldberger N, Bergman-Levy T, Haklai Z, Yoffe R, Davidson M, Susser E, et al.. COVID-19 and severe mental illness in Israel: testing, infection, hospitalization, mortality and vaccination rates in a countrywide study. Mol Psychiatry. 2022;27(7):3107–3114. doi: 10.1038/s41380-022-01562-2 PubMed DOI PMC

Nemani K, Li C, Olfson M, Blessing EM, Razavian N, Chen J, et al.. Association of Psychiatric Disorders With Mortality Among Patients With COVID-19. JAMA Psychiatry. 2021;78(4):380–386. doi: 10.1001/jamapsychiatry.2020.4442 PubMed DOI PMC

Ranger TA, Clift AK, Patone M, Coupland CAC, Hatch R, Thomas K, et al.. Preexisting Neuropsychiatric Conditions and Associated Risk of Severe COVID-19 Infection and Other Acute Respiratory Infections. JAMA Psychiatry. 2022;80(1):57–65. doi: 10.1001/jamapsychiatry.2022.3614 PubMed DOI PMC

Gibbs A, Maripuu M, Öhlund L, Widerström M, Nilsson N, Werneke U. COVID-19-associated mortality in individuals with serious mental disorders in Sweden during the first two years of the pandemic–a population-based register study. BMC Psychiatry. 2024;24(1):189. doi: 10.1186/s12888-024-05629-y PubMed DOI PMC

Descamps A, Frenkiel J, Zarca K, Laidi C, Godin O, Launay O, et al.. Association between mental disorders and COVID-19 outcomes among inpatients in France: A retrospective nationwide population-based study. J Psychiatr Res. 2022;155:194–201. doi: 10.1016/j.jpsychires.2022.08.019 PubMed DOI PMC

Allen B, El Shahawy O, Rogers ES, Hochman S, Khan MR, Krawczyk N. Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January–October 2020. J Public Health. 2021;43(3):462–465. doi: 10.1093/pubmed/fdaa241 PubMed DOI PMC

Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30–39. doi: 10.1038/s41380-020-00880-7 PubMed DOI PMC

Wen-Jan T, Hailey MK, Robert PL. Assessing the risk of COVID-19 reinfection and severe outcomes among individuals with substance use disorders: a retrospective study using real-world electronic health records. BMJ Open. 2023;13(12). doi: 10.1136/bmjopen-2023-074993 PubMed DOI PMC

Schwarzinger M, Luchini S, Teschl M, Alla F, Mallet V, Rehm J. Mental disorders, COVID-19-related life-saving measures and mortality in France: A nationwide cohort study. PLoS Med. 2023;20(2):e1004134. doi: 10.1371/journal.pmed.1004134 PubMed DOI PMC

Lee D-W, Bae YS, Lee J-R, Sohn JH, Lee H, Lee JY. COVID-19 vaccination, incidence, and mortality rates among individuals with mental disorders in South Korea: A nationwide retrospective study. Asian J Psychiatr. 2023:85. doi: 10.1016/j.ajp.2023.103600 PubMed DOI PMC

Formánek T, Wolfová K, Melicharová H, Mladá K, Wiedemann A, Chen D, et al.. COVID-19 and All-cause Mortality following First-ever SARS-CoV-2 Infection in Individuals with Pre-existing Mental Disorders: A National Cohort Study from Czechia 2023. [accessed: 15/05/2024]. Available from: https://osf.io/4fe6n/. PubMed PMC

Krupchanka D, Winkler P. State of mental healthcare systems in Eastern Europe: do we really understand what is going on? BJPsych Int. 2016;13(4):96–99. doi: 10.1192/s2056474000001446 PubMed DOI PMC

Winkler P, Krupchanka D, Roberts T, Kondratova L, Machů V, Höschl C, et al.. A blind spot on the global mental health map: a scoping review of 25 years’ development of mental health care for people with severe mental illnesses in central and eastern Europe. Lancet Psychiatry. 2017;4(8):634–642. doi: 10.1016/S2215-0366(17)30135-9 PubMed DOI

Pec O. Mental health reforms in the Czech Republic. BJPsych Int. 2019;16(1):4–6. doi: 10.1192/bji.2017.27 PubMed DOI PMC

Broulikova HM, Dlouhy M, Winkler P. Expenditures on Mental Health Care in the Czech Republic in 2015. Psychiatry Q. 2020;91(1):113–125. doi: 10.1007/s11126-019-09688-3 PubMed DOI PMC

Nechanská B, Jann J, Nováková Z, Kudrna K, Slábová V, Pašingerová R. Psychiatric Care 2016. Prague: Insititute of Health Information and Statistics, 2017.

Ministry of Health of the Czech Republic. Stratefy of the Reform of Psychiatric Care. 2013.

Komenda M, Panoška P, Bulhart V, Žofka J, Brauner T, Hak J, et al.. COVID-19: Overview of the Current Situation in Czechia Prague: Ministry of Health of the Czech Republic; 2020. [accessed: 16/07/2024]. Available from: https://onemocneni-aktualne.mzcr.cz/covid-19.

Ministry of Health of the Czech Republic. COVID-19 Vaccination Strategy in Czech Republic. 2020.

Pedersen CB, Mors O, Bertelsen A, Waltoft BL, Agerbo E, McGrath JJ, et al.. A Comprehensive Nationwide Study of the Incidence Rate and Lifetime Risk for Treated Mental Disorders. JAMA Psychiatry. 2014;71(5):573–581. doi: 10.1001/jamapsychiatry.2014.16 PubMed DOI

VanderWeele TJ, Shpitser I. A New Criterion for Confounder Selection. Biometrics. 2011;67(4):1406–1413. doi: 10.1111/j.1541-0420.2011.01619.x PubMed DOI PMC

VanderWeele TJ. Principles of confounder selection. Eur J Epidemiol. 2019;34(3):211–219. doi: 10.1007/s10654-019-00494-6 PubMed DOI PMC

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8 PubMed DOI

Office for National Statistics. Coronavirus and mortality in England and Wales methodology 2021. [accessed: 15/05/2024]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/methodologies/coronavirusandmortalityinenglandandwalesmethodology.

Stensrud MJ, Hernán MA. Why Test for Proportional Hazards? JAMA. 2020;323(14):1401–1402. doi: 10.1001/jama.2020.1267 PubMed DOI PMC

Wasserstein RL, Lazar NA. The ASA Statement on p-Values: Context, Process, and Purpose. Am Stat. 2016;70(2):129–133. doi: 10.1080/00031305.2016.1154108 DOI

R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2024.

Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Web Site and R Package for Computing E-values. Epidemiology. 2018;29(5). doi: 10.1097/EDE.0000000000000864 PubMed DOI PMC

Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al.. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020;11(1). doi: 10.1038/s41467-020-19478-2 PubMed DOI PMC

Lin M, Lucas HC, Shmueli G. Too Big to Fail: Large Samples and the p-Value Problem. Inf Syst Res. 2013;24(4):906–917. doi: 10.1287/isre.2013.0480 DOI

VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017;167(4):268–274. doi: 10.7326/M16-2607 PubMed DOI

Hassan L, Sawyer C, Peek N, Lovell K, Carvalho AF, Solmi M, et al.. Heightened COVID-19 Mortality in People With Severe Mental Illness Persists After Vaccination: A Cohort Study of Greater Manchester Residents. Schizophr Bull. 2023;49(2):275–284. doi: 10.1093/schbul/sbac118 PubMed DOI PMC

Kisely S, Crowe E, Lawrence D. Cancer-Related Mortality in People With Mental Illness. JAMA Psychiatry. 2013;70(2):209–217. doi: 10.1001/jamapsychiatry.2013.278 PubMed DOI

Cunningham R, Sarfati D, Stanley J, Peterson D, Collings S. Cancer survival in the context of mental illness: a national cohort study. Gen Hosp Psychiatry. 2015;37(6):501–506. doi: 10.1016/j.genhosppsych.2015.06.003 PubMed DOI

Heiberg IH, Jacobsen BK, Balteskard L, Bramness JG, Næss Ø, Ystrom E, et al.. Undiagnosed cardiovascular disease prior to cardiovascular death in individuals with severe mental illness. Acta Psychiatr Scand. 2019;139(6):558–571. doi: 10.1111/acps.13017 PubMed DOI PMC

Van Nieuwenhuizen A, Henderson C, Kassam A, Graham T, Murray J, Howard LM, et al.. Emergency department staff views and experiences on diagnostic overshadowing related to people with mental illness. Epidemiol Psychiatr Sci. 2013;22(3):255–262. doi: 10.1017/S2045796012000571 PubMed DOI PMC

Riou J, Panczak R, Althaus CL, Junker C, Perisa D, Schneider K, et al.. Socioeconomic position and the COVID-19 care cascade from testing to mortality in Switzerland: a population-based analysis. Lancet Public Health. 2021;6(9):e683–e691. doi: 10.1016/S2468-2667(21)00160-2 PubMed DOI PMC

O’Neill B, Kalia S, Hum S, Gill P, Greiver M, Kirubarajan A, et al.. Socioeconomic and immigration status and COVID-19 testing in Toronto, Ontario: retrospective cross-sectional study. BMC Public Health. 2022;22(1):1067. doi: 10.1186/s12889-022-13388-2 PubMed DOI PMC

Yinjie Z, Ming-Jie D, Hermien HD, Roel DF, Louise HD, Jochen OM. Association between socioeconomic status and self-reported, tested and diagnosed COVID-19 status during the first wave in the Northern Netherlands: a general population-based cohort from 49 474 adults. BMJ Open. 2021;11(3):e048020. doi: 10.1136/bmjopen-2020-048020 PubMed DOI PMC

Mena GE, Martinez PP, Mahmud AS, Marquet PA, Buckee CO, Santillana M. Socioeconomic status determines COVID-19 incidence and related mortality in Santiago, Chile. Science. 2021;372(6545):eabg5298. doi: 10.1126/science.abg5298 PubMed DOI PMC

Calling S, Ohlsson H, Sundquist J, Sundquist K, Kendler KS. Socioeconomic status and alcohol use disorders across the lifespan: A co-relative control study. PLoS ONE. 2019;14(10). doi: 10.1371/journal.pone.0224127 PubMed DOI PMC

Manhica H, Straatmann VS, Lundin A, Agardh E, Danielsson A-K. Association between poverty exposure during childhood and adolescence, and drug use disorders and drug-related crimes later in life. Addiction. 2021;116(7):1747–1756. doi: 10.1111/add.15336 PubMed DOI PMC

Werner S, Malaspina D, Rabinowitz J. Socioeconomic Status at Birth Is Associated With Risk of Schizophrenia: Population-Based Multilevel Study. Schizophr Bull. 2007;33(6):1373–1378. doi: 10.1093/schbul/sbm032 PubMed DOI PMC

Yanan L, Lei Z, Ping H, Lihua P, Chao G, Xiaoying Z. Individual-level and area-level socioeconomic status (SES) and schizophrenia: cross-sectional analyses using the evidence from 1.9 million Chinese adults. BMJ Open. 2019;9(9). doi: 10.1136/bmjopen-2018-026532 PubMed DOI PMC

Dickerson F, Stallings CR, Origoni AE, Vaughan C, Khushalani S, Schroeder J, et al.. Cigarette Smoking Among Persons With Schizophrenia or Bipolar Disorder in Routine Clinical Settings, 1999–2011. Psychiatr Serv. 2013;64(1):44–50. doi: 10.1176/appi.ps.201200143 PubMed DOI

Scheewe TW, Jörg F, Takken T, Deenik J, Vancampfort D, Backx FJG, et al.. Low Physical Activity and Cardiorespiratory Fitness in People With Schizophrenia: A Comparison With Matched Healthy Controls and Associations With Mental and Physical Health. Front Psych. 2019:10. doi: 10.3389/fpsyt.2019.00087 PubMed DOI PMC

Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al.. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77. doi: 10.1016/S2215-0366(19)30416-X PubMed DOI PMC

Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–68. doi: 10.1002/wps.20699 PubMed DOI PMC

Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy With Antipsychotics, Antidepressants, or Benzodiazepines and Mortality in Schizophrenia. Arch Gen Psychiatry. 2012;69(5):476–483. doi: 10.1001/archgenpsychiatry.2011.1532 PubMed DOI

Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–226. doi: 10.1002/wps.20060 PubMed DOI PMC

Cai G, Lin Y, Lu Y, He F, Morita K, Yamamoto T, et al.. Behavioural responses and anxiety symptoms during the coronavirus disease 2019 (COVID-19) pandemic in Japan: A large scale cross-sectional study. J Psychiatr Res. 2021;136:296–305. doi: 10.1016/j.jpsychires.2021.02.008 PubMed DOI PMC

Knowles KA, Olatunji BO. Anxiety and safety behavior usage during the COVID-19 pandemic: The prospective role of contamination fear. J Anxiety Disord. 2021;77:102323. doi: 10.1016/j.janxdis.2020.102323 PubMed DOI PMC

Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021;21(1):855. doi: 10.1186/s12879-021-06536-3 PubMed DOI PMC

Nørtoft E, Chubb B, Borglykke A. Obesity and healthcare resource utilization: comparative results from the UK and the USA. Obes Sci Pract. 2018;4(1):41–45. doi: 10.1002/osp4.148 PubMed DOI PMC

Kivimäki M, Batty GD, Pentti J, Shipley MJ, Sipilä PN, Nyberg ST, et al.. Association between socioeconomic status and the development of mental and physical health conditions in adulthood: a multi-cohort study. Lancet Public Health. 2020;5(3):e140–e149. doi: 10.1016/S2468-2667(19)30248-8 PubMed DOI

Azagba S, Sharaf MF, Xiao LC. Disparities in health care utilization by smoking status in Canada. Int J Public Health. 2013;58(6):913–925. doi: 10.1007/s00038-013-0452-7 PubMed DOI

Haapanen-Niemi N, Miilunpalo S, Vuori I, Pasanen M, Oja P. The impact of smoking, alcohol consumption, and physical activity on use of hospital services. Am J Public Health. 1999;89(5):691–698. doi: 10.2105/ajph.89.5.691 PubMed DOI PMC

Elrashidi MY, Jacobson DJ, St. Sauver J, Fan C, Lynch BA, Rutten LJF, et al.. Body Mass Index Trajectories and Healthcare Utilization in Young and Middle-aged Adults. Medicine. 2016;95(2). doi: 10.1097/MD.0000000000002467 PubMed DOI PMC

Tian J, Venn AJ, Blizzard L, Patton GC, Dwyer T, Gall SL. Smoking status and health-related quality of life: a longitudinal study in young adults. Qual Life Res. 2016;25(3):669–685. doi: 10.1007/s11136-015-1112-6 PubMed DOI

Virdis A, Giannarelli C, Fritsch Neves M, Taddei S, Ghiadoni L. Cigarette Smoking and Hypertension. Curr Pharm Des. 2010;16(23):2518–2525. doi: 10.2174/138161210792062920 PubMed DOI

Hall JE. do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-Induced Hypertension. Circ Res. 2015;116(6):991–1006. doi: 10.1161/CIRCRESAHA.116.305697 PubMed DOI PMC

Powell-Wiley TM, Poirier P, Burke LE, Després J-P, Gordon-Larsen P, Lavie CJ, et al.. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984–e1010. doi: 10.1161/CIR.0000000000000973 PubMed DOI PMC

Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of heart failure: A systematic review and meta-analysis of prospective studies. Eur J Prev Cardiol. 2019;26(3):279–288. doi: 10.1177/2047487318806658 PubMed DOI

Rosenbaum PR, Rubin DB. The Bias Due to Incomplete Matching. Biometrics. 1985;41(1):103–116. doi: 10.2307/2530647 PubMed DOI

Zhang J-j, Dong X, Liu G-h, Gao Y-d. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clin Rev Allergy Immunol. 2023;64(1):90–107. doi: 10.1007/s12016-022-08921-5 PubMed DOI PMC

van Zwieten A, Tennant PWG, Kelly-Irving M, Blyth FM, Teixeira-Pinto A, Khalatbari-Soltani S. Avoiding overadjustment bias in social epidemiology through appropriate covariate selection: a primer. J Clin Epidemiol. 2022;149:127–136. doi: 10.1016/j.jclinepi.2022.05.021 PubMed DOI

Deaths with COVID-19 and from all-causes following first-ever SARS-CoV-2 infection in individuals with preexisting mental disorders: A national cohort study from Czechia